Skip to main content

Advertisement

SpringerLink
Log in

HNRNPC as a candidate biomarker for chemoresistance in gastric cancer

  • Original Article
  • Published:
Tumor Biology

Abstract

Chemoresistance is a major cause of treatment failure and high mortality in advanced gastric cancer (AGC). Currently, the mechanism of chemoresistance remains unclear, and there is no biomarker to accurately predict the efficacy of chemotherapy. In the present study, we established human gastric cancer (GC) cell lines resistant to 5-fluorouracil (5FU), paclitaxel (TA), or cisplatin (DDP) by gradient drug treatment and generated a novel monoclonal antibody 5B2 targeting heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) overexpressed in chemoresistant GC cells. Overexpressing HNRNPC in GC cells promoted chemoresistance, and knockdown of HNRNPC by small interfering RNA (siRNA) reversed chemoresistance. By utilizing available datasets, we demonstrated that high level of HNRNPC transcript indicated poor overall survival (OS) and free of progression (FP). HNRNPC expression was negatively correlated with OS of GC patients treated with 5FU-based drugs and with time to progression (TTP) of GC patients treated with CF regimen. These data suggest the potential usefulness of HNRNPC as a prognostic and therapeutic marker of GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidem Biomar. 2014;23(5):700–13.

  3. Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer. Meta-analysis of randomized clinical trials. Acta Cir Bras. 2008;23(6):520–30.

  4. Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2014;14(8):887–900.

    Article  CAS  PubMed  Google Scholar 

  5. Kim JG. Molecular targeted therapy for advanced gastric cancer. Korean J Intern Med. 2013;28(2):149–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wong R, Cunningham D. Optimising treatment regimens for the management of advanced gastric cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2009;20(4):605–8.

    Article  CAS  Google Scholar 

  7. Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2015;16(1):117–22.

    Article  CAS  PubMed  Google Scholar 

  8. Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother CII. 2014;63(6):581–6.

    Article  CAS  PubMed  Google Scholar 

  9. Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527–37.

    Article  CAS  PubMed  Google Scholar 

  10. Krueger P, Nitz C, Foster R, MacDonald C, Gelber O, Lalehzadeh G, et al. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells. Cancer Immunol Immunother CII. 2003;52(6):367–77.

    CAS  PubMed  Google Scholar 

  11. Mattes MJ, Look K, Furukawa K, Pierce VK, Old LJ, Lewis Jr JL, et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res. 1987;47(24 Pt 1):6741–50.

    CAS  PubMed  Google Scholar 

  12. Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3.

    PubMed  PubMed Central  Google Scholar 

  13. Zhao W, Wang L, Han H, Jin K, Lin N, Guo T, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel alpha2delta1 subunit. Cancer Cell. 2013;23(4):541–56.

    Article  CAS  PubMed  Google Scholar 

  14. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5(5):292–302.

    Article  CAS  PubMed  Google Scholar 

  15. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov. 2002;1(12):951–60.

    Article  CAS  PubMed  Google Scholar 

  16. Szoke D, Gyorffy A, Surowiak P, Tulassay Z, Dietel M, Gyorffy B. Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer. Onkologie. 2007;30(8–9):421–6.

    CAS  PubMed  Google Scholar 

  17. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One. 2011;6(2):e16694.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol. 2010;2(7):287–94.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets. 2011;11(5):613–23.

    Article  CAS  PubMed  Google Scholar 

  20. Xu HW, Xu L, Hao JH, Qin CY, Liu H. Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res. 2010;38(1):34–42.

    Article  PubMed  Google Scholar 

  21. Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 1998;83(9):1917–22.

    Article  CAS  PubMed  Google Scholar 

  22. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol Rep. 2005;14(3):609–15.

    CAS  PubMed  Google Scholar 

  23. Shen XM, Zhou C, Lian L, Li LQ, Li W, Tao M. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochem Biophys. 2014.

  24. Canadas I, Rojo F, Taus A, Arpi O, Arumi-Uria M, Pijuan L, et al. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(4):938–50.

    Article  CAS  Google Scholar 

  25. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.

    Article  CAS  PubMed  Google Scholar 

  26. Yoon JH, Ahn SG, Lee BH, Jung SH, Oh SH. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. Biochem Pharmacol. 2012;83(6):747–57.

    Article  CAS  PubMed  Google Scholar 

  27. Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One. 2013;8(5):e65309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Burd CG, Swanson MS, Gorlach M, Dreyfuss G. Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci U S A. 1989;86(24):9788–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Liang CR, Leow CK, Neo JC, Tan GS, Lo SL, Lim JW, et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 2005;5(8):2258–71.

    Article  CAS  PubMed  Google Scholar 

  30. Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS. hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acids Res. 1998;26(14):3418–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lee SY, Park JH, Kim S, Park EJ, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J. 2005;388(Pt 1):7–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Christian KJ, Lang MA, Raffalli-Mathieu F. Interaction of heterogeneous nuclear ribonucleoprotein C1/C2 with a novel cis-regulatory element within p53 mRNA as a response to cytostatic drug treatment. Mol Pharmacol. 2008;73(5):1558–67.

    Article  CAS  PubMed  Google Scholar 

  33. Blume SW, Jackson NL, Frost AR, Grizzle WE, Shcherbakov OD, Choi H, et al. Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. Exp Mol Pathol. 2010;88(3):341–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A. 1993;90(23):11217–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Park YM, Hwang SJ, Masuda K, Choi KM, Jeong MR, Nam DH, et al. Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4. Mol Cell Biol. 2012;32(20):4237–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We deeply appreciate Dr. Györffy (Semmelweis University, Budapest, Hungary) and Dr. Green JE (Transgenic Oncogenesis and Genomics Section, Center for Cancer Research, National Cancer Institute) for providing gene expression datasets of gastric cancer patients. This study was supported by National Basic Research Program of China (2015CB553906).

Author information

Author notes

  1. Hao Huang

    Present address: Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences, Beijing, 100021, China

Authors and Affiliations

  1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, 100142, China

    Hao Huang, Yong Han, Cheng Zhang, Jian Wu, Junnan Feng, Like Qu & Chengchao Shou

  2. Department of Pathology, Zhejiang Provincial People’s Hospital, Zhejiang, 310014, China

    Yong Han

Authors
  1. Hao Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junnan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Like Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chengchao Shou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chengchao Shou.

Ethics declarations

Conflicts of interest

None

Additional information

Hao Huang and Yong Han contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, H., Han, Y., Zhang, C. et al. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumor Biol. 37, 3527–3534 (2016). https://doi.org/10.1007/s13277-015-4144-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4144-1

Keywords

Search

Navigation